Search

314 results for "lecanemab".

Research summaries 285

Showing the best 200 of 285, 61–70, page 7 of 20. Filter these by subject, year and score in the research library →

1. Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension studyResearch summary

   Research summaries · alzhub.org/study/long-term-safety-and-efficacy-of-lecanemab-in-early-alzheimer-s-41355080

   Introduction In Clarity AD, lecanemab reduced markers of amyloid in early symptomatic Alzheimer's disease and slowed cognitive and functional decline at 18 months. Herein, we report 36-month data from the ongoing open-label …

2. Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysisResearch summary

   Research summaries · alzhub.org/study/monoclonal-therapy-with-lecanemab-in-the-treatment-of-mild-alzheimer-39638097

   … plaques in the brain. Lecanemab (BAN2401), a humanized IgG1 monoclonal antibody, binds with high affinity to Amyloid-β protofibrils. It is the first monoclonal antibody for Alzheimer's disease to receive full FDA approval. This …

3. Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System databaseResearch summary

   Research summaries · alzhub.org/study/post-marketing-safety-concerns-with-lecanemab-a-pharmacovigilance-39780222

   Background The safety data of lecanemab in the post-marketing period has yet to be fully investigated in the current literature. We aimed to identify and characterise the safety profile of lecanemab in the post-marketing period. …

4. Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer's disease in Eastern ChinaResearch summary

   Research summaries · alzhub.org/study/real-world-experience-with-baseline-characteristics-and-safety-of-41396015

   … preliminary safety of lecanemab for AD in Zhejiang Province, and to evaluate the efficacy of plasma biomarkers for patient screening.MethodsThis multi-center study included 190 patients with AD in Zhejiang Province, who completed …

5. Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experienceResearch summary

   Research summaries · alzhub.org/study/real-world-implementation-of-lecanemab-and-donanemab-in-an-italian-41857623

   … ARIA-H in 15% (3/20). In lecanemab-treated patients, asymptomatic ARIA-H occurred in 11% (1/9). Infusion-related reactions occurred in 21% (6/29) of treatment courses and were manageable with standardized premedication. Among 11 …

6. Real-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting systemResearch summary

   Research summaries · alzhub.org/study/real-world-safety-profile-of-lecanemab-a-disproportionality-analysis-cbaaba6e

   Background Lecanemab, an antiamyloid monoclonal antibody, has emerged as a treatment option for Alzheimer disease. However, there is a pressing need for real-world evidence to inform clinical practice, particularly regarding its …

7. Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and ChallengesResearch summary

   Research summaries · alzhub.org/study/review-of-donanemab-and-lecanemab-in-mild-dementia-stage-of-alzheimer-41966037

   … antibodies (mAbs), notably lecanemab and donanemab, which target Aβ pathology in early-stage AD. This review explores the clinical efficacy, safety profile, and limitations of lecanemab and donanemab, emphasizing key findings …

8. The social value of lecanemab for patients with early Alzheimer's disease in JapanResearch summary

   Research summaries · alzhub.org/study/the-social-value-of-lecanemab-for-patients-with-early-alzheimer-s-42108615

   … the social value of lecanemab in Japan.MethodsThe social value was evaluated using a cost-effectiveness model. The intervention was lecanemab added to the standard of care (SOC), and the comparator was SOC alone. The effect of …

9. A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databasesResearch summary

   Research summaries · alzhub.org/study/a-real-world-pharmacovigilance-study-of-adverse-drug-reactions-40290431

   Background Lecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer's disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited …

10. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's diseaseResearch summary

    Research summaries · alzhub.org/study/aria-in-patients-treated-with-lecanemab-ban2401-in-a-phase-2-study-in-36949897

    Introduction Lecanemab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that preferentially targets soluble aggregated Aβ species (protofibrils) with activity at amyloid plaques. Amyloid-related imaging abnormalities …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

28381 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-05. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.